Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity

Clinical and Vaccine Immunology

Volumn 18, Issue 1, 2011, Pages 150-160

  Appledorn, Daniel M ^a   Aldhamen, Yasser A ^a   Godbehere, Sarah ^a   Seregin, Sergey S ^a   Amalfitano, Andrea ^a,b  

^a Michigan State University ^*  (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12P40; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TOLL LIKE RECEPTOR AGONIST;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; IN VIVO STUDY; INNATE IMMUNITY; MACROPHAGE; MALE; MOUSE; MOUTH CAVITY; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADENOVIRUSES, HUMAN; ADMINISTRATION, SUBLINGUAL; AIDS VACCINES; ANIMALS; GENE PRODUCTS, GAG; GENETIC VECTORS; HIV ANTIGENS; HUMANS; IMMUNITY, MUCOSAL; MALE; MICE; MICE, INBRED C57BL; MOUTH; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTORS; VACCINATION;

EID: 78650919398     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00341-10     Document Type: Article

References (32)

1. Abbink, P., et al. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81:4654-4663.
2. Ahlers, J. D., and I. M. Belyakov. 2010. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol. 31:120-130.
3. Appledorn, D. M., et al. 2010. A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target. PloS One 5:e9579.
4. Appledorn, D. M., S. Patial, S. Godbehere, N. Parameswaran, and A. Amalfitano. 2009. TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses. J. Innate Immun. 1:376-388.
5. Appledorn, D. M., et al. 2008. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J. Immunol. 181:2134-2144.
6. Belyakov, I. M., and J. D. Ahlers. 2008. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine. Trends Immunol. 29:574-585.
7. Buchbinder, S. P., et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
8. Casimiro, D. R., et al. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305-6313.
9. Croyle, M. A., et al. 2008. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PloS One 3:e3548.
10. Cuburu, N., et al. 2009. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J. Immunol. 183:7851-7859.
11. Cuburu, N., et al. 2007. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25:8598-8610. (Pubitemid 350192038)
12. Draper, S. J., and J. L. Heeney. 2010. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8:62-73.
13. Dudding, B. A., et al. 1972. Enteric immunization with live adenovirus type 21 vaccine. I. Tests for safety, infectivity, immunogenicity, and potency in volunteers. Infect. Immun. 5:295-299.
14. Flynn, N. M., et al. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-665.
15. Frew, A. J. 2008. Sublingual immunotherapy. New Engl. J. Med. 358:2259-2264.
16. Hartman, Z. C., et al. 2007. Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J. Virol. 81:1796-1812.
17. Lemiale, F., et al. 2007. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 25:2074-2084. (Pubitemid 46227670)
18. Mattapallil, J. J., et al. 2005. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434:1093-1097.
19. Mattapallil, J. J., and M. Roederer. 2008. Mucosa and vaccine-induced immune protection in nonhuman primates. Curr. Opin. HIV AIDS 3:387-392.
20. McMichael, A. J., P. Borrow, G. D. Tomaras, N. Goonetilleke, and B. F. Haynes. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. 10:11-23.
21. Ng, P., and F. L. Graham. 2002. Construction of first-generation adenoviral vectors. Methods Mol. Med. 69:389-414.
22. Nwanegbo, E., et al. 2004. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11:351-357.
23. Pitisuttithum, P., et al. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671.
24. Pulendran, B., and R. Ahmed. 2006. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124:849-863.
25. Rerks-Ngarm, S., et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New Engl. J. Med. 361:2209-2220.
26. Seregin, S. S., and A. Amalfitano. 2009. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin. Biol. Ther. 9:1521-1531.
27. Song, J. H., et al. 2009. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J. Immunol. 182:6851-6860.
28. Song, J. H., et al. 2008. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl. Acad. Sci. U. S. A. 105:1644-1649.
29. Top, F. H., Jr., B. A. Dudding, P. K. Russell, and E. L. Buescher. 1971. Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am. J. Epidemiol. 94:142-146.
30. Top, F. H., Jr., et al. 1971. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J. Infect. Dis. 124:148-154.
31. Van den Broeck, W., A. Derore, and P. Simoens. 2006. Anatomy and nomenclature of murine lymph nodes: descriptive study and nomenclatory standardization in BALB/cAnNCrl mice. J. Immunol. Methods 312:12-19. (Pubitemid 43795993)
32. Xiang, Z. Q., et al. 2003. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol. 77:10780-10789.